Vericel to Present at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 4:30 p.m. ET. The presentation will be led by President and CEO Nick Colangelo. A live webcast of the event will be available on Vericel's Investor Relations website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing MACI® and Epicel®, with exclusive rights for NexoBrid® in North America.

News Market Reaction – VCEL

-3.43%

-3.43% Session move

In the trading session that priced this news, VCEL declined 3.43%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 20^th Annual Needham Virtual Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Thursday, April 15, 2021, at 4:30 p.m. Eastern Time.

A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid^®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved.

Investor Contacts:
Eric Burns
ir@vcel.com
+1 734-418-4411

FAQ

When will Vericel present at the Needham Virtual Healthcare Conference?

Vericel will present on April 15, 2021, at 4:30 p.m. Eastern Time.

Who is presenting for Vericel at the conference?

Nick Colangelo, President and CEO of Vericel, will present the company overview.

Where can I watch the Vericel presentation live?

The live webcast can be found on Vericel's Investor Relations website.

What are the main products offered by Vericel Corporation?

Vericel markets MACI® and Epicel®, therapies for sports medicine and severe burn care.

What is NexoBrid and its relation to Vericel?

NexoBrid is a registration-stage product for severe burns, and Vericel holds exclusive North American rights.